Abivax Shares Rise on Positive Phase 3 Results and Analyst Upgrades

Abivax shares are trading higher after LifeSci Capital, among others, raised its price target to $101 and reaffirmed an Outperform rating following the company's impressive Phase 3 results for obefazimod in treating ulcerative colitis.